Canberra, Australian Government Department of Health and Aged Care, 2026.
Canberra, Australian Government Department of Health and Aged Care, 2026.
Sydney, ASHM, 2025.
Assessment of trends in treatment for hepatitis C through May 2025.
Sydney, ASHM, 2026.
Includes data regarding hepatitis B, as well as estimates of viral hepatitis testing and liver cancer.
Melbourne, Doherty Institute, 2026.
Adelaide, SA Health CDC Branch, 2025.
Canberra, Hepatitis Australia, 2026.
Hub for information on hepatitis D, developed in collaboration with hepatitis community organisations, infectious disease experts, and people with lived experience of hepatitis B and hepatitis D.
Sydney, INHSU, 2025.
Shows how practical strategies—such as peer-led models, simplified workflows, and flexible referral pathways—can be applied in different settings to close gaps in testing and treatment.
Sydney, Medical Journal of Australia, 2026.
Calls for an urgent change in HDV testing policy and funding to implement reflex HDV antibody (anti-HDV) testing for all people diagnosed with HBV infection.
Canberra, HepLink Australia, 2026.
Bulk billed telehealth service which provides remote consultations and prescriptions for hepatitis C treatment.
London, Elsevier, 2025.
Discusses the potential benefits and risks of expansion, implementation considerations, public health questions, and data needs surrounding the expansion of treatment eligibility. Concludes that there is a strong public health and community rationale for expanding treatment eligibility for people living with chronic hepatitis B.
Melbourne, Peter Doherty Institute for Infection and Immunity, 2022.
Dr Thomas Tu, Founder and Director, HepBCommunity.org and President, Australian Centre for Hepatitis Virology answers the question: What do we mean by Hepatitis B cure? The FAQs are a collection of short videos answering key questions relating to HBV cure research.
London, Elsevier, 2025.
Presents the benefits and risks of expanding treatment eligibility. Concludes that the benefits of reduced hepatic damage and carcinogenic stimuli greatly outweigh the risks.
Sydney, Centre for Social Research in Health, 2005.
Antistigma campaigns and intervention messages have the potential to reduce the harmful stigmatization of various conditions (e.g., HIV/AIDS, mental illness). However, antistigma messages also have the capacity to cause adverse unintended effects.
Sydney, National Prisons Hepatitis Network, 2026.
Comprehensive and interactive resource for blood-borne virus surveillance data for Australian prisons, including both national and jurisdictional datasets and data for specific sub-populations.
Sydney, Medical Journal of Australia, 2026.
Globally, one-in-nine incarcerated people have a history of IV drug use. In Australia and New Zealand, it’s one-in-two. The University of New South Wales (UNSW) has become the first to quantify, in two systematic reviews, both the prevalence of blood-borne diseases for incarcerated people, and access to a handful of well-known healthcare programs. It found that no country, worldwide, had all the programs available.
For enquiries or feedback, please contact the librarian at Librarian@hepatitissa.asn.au.
| Address: | 3 Hackney Road Hackney SA 5069 |
| Phone: | (08) 8362 8443 |
| Fax: | (08) 8362 8559 |
| Email: | Librarian@hepatitissa.asn.au |
| Post: | PO Box 782 Kent Town SA 5071 |
Monday – Friday
9am to 5pm
Hepatitis SA is a non-profit, community-based organisation that provides information, education and support services to South Australians affected by hepatitis B and hepatitis C.